The company has ticked off an important milestone with its first purchase order coming from Haleon for its paracetamol soft gel liquid analgesic into the U.K market.
Haleon is one of the world's largest independent consumer healthcare companies, utilising Wellnex's innovate product for use in arguably the most trusted pain relief brand in Australia and across the world, Panadol. Haleon currently has a market cap of roughly ~$65B AUD, marking this transaction as serious validation of the companies business model coupled with the legitimacy of its product range
Along with the expansion into the U.K where the company is also planning its dual listing on the London Stock Exchange, the company is also in the final stages of its imminent launch into the U.A.E market with its product range, opening up a further distribution channel.
Wellnex has already been supplying its product range to Haleon through its Panadol brand in Australia prior to this expansion into the U.K market
